Pfizer Inc. (PFE)
| Market Cap | 147.09B |
| Revenue (ttm) | 62.79B |
| Net Income (ttm) | 9.83B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.73 |
| PE Ratio | 15.04 |
| Forward PE | 8.33 |
| Dividend | $1.72 (6.74%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 96,005,546 |
| Open | 25.40 |
| Previous Close | 25.51 |
| Day's Range | 25.25 - 25.95 |
| 52-Week Range | 20.92 - 27.69 |
| Beta | 0.42 |
| Analysts | Hold |
| Price Target | 27.44 (+6.07%) |
| Earnings Date | Nov 4, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $27.44, which is an increase of 6.07% from the latest price.
News
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice Pr...
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached the...
Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript
Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST Company Participants Francesca DeMartino - Chief Investor Relations O...
Pfizer to buy Metsera in deal worth up to $10 billion
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted ...
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical de...
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration.
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.
The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.
Dividend Income: Lanny's September 2025 Summary
In September, we (my wife and I) received a dividend income total of $5,342.09. Our dividend income went up almost $1,000 from last year. We had more stocks increase last month, but the increases this...
U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer
The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will ...
Pfizer wins $10 billion bidding war for obesity drug developer
Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Pfizer clinches $10 billion Metsera deal, outbidding Novo Nordisk
Pfizer acquires Metsera for $10 billion, cementing their new obesity treatment strategy. The purchase concludes a weeklong bidding frenzy between the New York-based pharmaceutical company and Danish h...
Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer
AbbVie's and Pfizer's Q3 earnings and dividend updates prompt a rating upgrade to Hold for ABBV and reiteration of Sell for PFE. PFE's higher yield (almost 7%) and single-digit P/E (FY1 P/E is ~8x onl...
Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war
Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.
Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer
Revised transaction values Metsera at up to $86.25 per share Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement a...
Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports
Pfizer has submitted a sweetened bid for obesity drug developer Metsera , as its fight against rival Novo Nordisk escalates, Bloomberg News reported on Friday.
Pfizer: The Storm Has Passed -- Tailwinds Ahead
Pfizer Inc. remains a Strong Buy with a $33 price target, implying 33% upside over 12-18 months, driven by undervaluation and sector tailwinds. Despite Fiscal Q3 2025 revenue and EPS declines, PFE's f...
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
The Delaware Chancery Court denied Pfizer Inc.'s (NYSE:PFE) request for a temporary restraining order to prevent Metsera, Inc. (NASDAQ:MTSR) from terminating the existing merger agreement in favor of...
Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle
A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 billion battle with U.S. rival Pfizer to win Metsera's obesity drug assets.
Pfizer's Slow Burn Comeback
Pfizer offers a 7% dividend yield, providing steady income despite stagnant share performance in recent months. COVID-19 product sales have sharply declined, with Paxlovid down 55% and vaccine revenue...
Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude
FAA will reduce air traffic by 10% across 40 major markets due to staffing shortages from the government shutdown, impacting 3,500-4,000 flights daily. Pfizer (PFE) has matched Novo Nordisk's bid for ...
Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman
Evan David Seigerman, BMO, joins 'Fast Money' to talk bidding wars in the pharma space, Novo Nordisk dropping on earnings, and more.
Pfizer Responds to Delaware Chancery Court Ruling
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order...
Pfizer preparing to raise its bid for Metsera, WSJ reports
Pfizer is preparing to sweeten its offer again for Metsera , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk
Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.